公开(公告)号：EP3126346B1

公开(公告)日：2018-07-11

申请号：EP15713527.8

申请日：2015-04-02

申请人： SANOFI

发明人： SCHWINK, Lothar ,  BUNING, Christian ,  GLOMBIK, Heiner ,  GOSSEL, Matthias ,  KADEREIT, Dieter ,  HALLAND, Nis ,  LOHMANN, Matthias ,  PÖVERLEIN, Christoph ,  RITTER, Kurt

IPC分类号： C07D401/12 ,  C07D207/26 ,  A61K31/402 ,  A61K31/4439 ,  A61P3/00

CPC分类号： C07D401/12 ,  A61K31/155 ,  A61K31/402 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  C07D207/26 ,  C07D207/273 ,  A61K2300/00

摘要： The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

公开(公告)号：EP1874737B1

公开(公告)日：2010-08-04

申请号：EP06723959.0

申请日：2006-04-01

申请人： sanofi-aventis

发明人： DEFOSSA, Elisabeth ,  SCHOENAFINGER, Karl ,  JAEHNE, Gerhard ,  BUNING, Christian ,  TSCHANK, Georg ,  WERNER, Ulrich

IPC分类号： C07D235/28 ,  A61K31/4184 ,  A61P3/10

CPC分类号： C07D235/28

摘要： The invention relates to substituted 2-aminoalkylthio-benzimidazoles, in addition to the physiologically compatible salts thereof and physiologically functional derivatives thereof. The invention also relates to compounds of formula (I), wherein the radicals have the above-mentioned meaning, and the physiologically compatible salts thereof. Said compounds are suitable, for example, as medicaments for preventing and treating type 2 diabetes.

公开(公告)号：EP1863789A1

公开(公告)日：2007-12-12

申请号：EP06723255.3

申请日：2006-03-07

申请人： Sanofi-Aventis

发明人： DEFOSSA, Elisabeth ,  SCHOENAFINGER, Karl ,  JAEHNE, Gerhard ,  BUNING, Christian ,  TSCHANK, Georg ,  WERNER, Ulrich

IPC分类号： C07D401/04 ,  A61K31/4184 ,  A61P3/10

CPC分类号： C07D401/04

摘要： The invention relates to amide-substituted 8-N-benzimidazoles and to the physiologically compatible salts and physiologically functional derivatives of said compounds. The invention relates to compounds of formula (I), in which the groups are defined as cited in the description, in addition to the physiologically compatible salts of said compounds. The compounds are suitable for use, for example, as medicaments for the prevention and treatment of type 2 diabetes.

公开(公告)号：EP1778690A1

公开(公告)日：2007-05-02

申请号：EP05770568.3

申请日：2005-07-30

申请人： Sanofi-Aventis Deutschland GmbH

发明人： SCHOENAFINGER, Karl ,  JAEHNE, Gerhard ,  DEFOSSA, Elisabeth ,  BUNING, Christian ,  TSCHANK, Georg ,  WERNER, Ulrich

IPC分类号： C07D473/08 ,  A61K31/522 ,  A61P3/10

CPC分类号： C07D473/04

摘要： The invention relates to substituted 8-aminoalkoxi-xanthines and to the physiologically compatible salts thereof and physiologically functional derivatives. The invention also relates to compounds of formula (I), wherein the radicals have the above-mentioned meaning, in addition to the physiologically compatible salts thereof. The compounds are suitable, for example, as medicaments for the prevention and treatment of type 2 diabetes.

公开(公告)号：EP2978754B1

公开(公告)日：2017-05-10

申请号：EP14712667.6

申请日：2014-03-26

申请人： SANOFI

发明人： RUF, Sven ,  SADOWSKI, Thorsten ,  WIRTH, Klaus ,  SCHREUDER, Herman ,  BUNING, Christian ,  KALLUS, Christopher ,  STROBEL, Hartmut ,  WEHLAN, Hermut

IPC分类号： C07D413/10 ,  C07D263/32 ,  C07D271/10 ,  C07D277/30 ,  A61K31/426 ,  A61P9/00 ,  A61P11/08 ,  A61P19/02 ,  A61P23/00

CPC分类号： C07D271/10 ,  C07D263/32 ,  C07D277/30 ,  C07D413/06 ,  C07D413/10 ,  C07D413/14

公开(公告)号：EP2978754A1

公开(公告)日：2016-02-03

申请号：EP14712667.6

申请日：2014-03-26

申请人： SANOFI

发明人： RUF, Sven ,  SADOWSKI, Thorsten ,  WIRTH, Klaus ,  SCHREUDER, Herman ,  BUNING, Christian ,  KALLUS, Christopher ,  STROBEL, Hartmut ,  WEHLAN, Hermut

IPC分类号： C07D413/10 ,  C07D263/32 ,  C07D271/10 ,  C07D277/30 ,  A61K31/426 ,  A61P9/00 ,  A61P11/08 ,  A61P19/02 ,  A61P23/00

CPC分类号： C07D271/10 ,  C07D263/32 ,  C07D277/30 ,  C07D413/06 ,  C07D413/10 ,  C07D413/14

摘要： The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

公开(公告)号：EP2736888B1

公开(公告)日：2015-11-04

申请号：EP12738473.3

申请日：2012-07-25

申请人： SANOFI

发明人： RUF, Sven ,  PERNERSTORFER, Josef ,  SADOWSKI, Thorsten ,  HORSTICK, Georg ,  SCHREUDER, Herman ,  BUNING, Christian ,  WIRTH, Klaus

IPC分类号： C07D249/10 ,  C07D263/34 ,  C07D271/06 ,  C07D271/10 ,  C07D277/32 ,  C07D285/08 ,  C07D307/68 ,  A61K31/341 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/433 ,  A61P9/00 ,  A61P11/00 ,  A61P37/00 ,  A61P25/28

CPC分类号： C07D401/06 ,  A61K31/341 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/454 ,  A61K45/06 ,  C07D231/14 ,  C07D233/90 ,  C07D249/10 ,  C07D261/18 ,  C07D263/34 ,  C07D271/06 ,  C07D271/10 ,  C07D277/32 ,  C07D277/56 ,  C07D285/08 ,  C07D307/68

公开(公告)号：EP2668167A1

公开(公告)日：2013-12-04

申请号：EP12700866.2

申请日：2012-01-26

申请人： SANOFI

发明人： RUF, Sven ,  SADOWSKI, Thorsten ,  HORSTICK, Georg ,  SCHREUDER, Herman ,  BUNING, Christian ,  OLPP, Thomas ,  WIRTH, Klaus

IPC分类号： C07D231/14 ,  C07D275/03

CPC分类号： C07D231/38 ,  C07D275/02 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D405/12 ,  C07D417/04 ,  C07D487/04

摘要： The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R11, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

公开(公告)号：EP1651653B1

公开(公告)日：2011-11-23

申请号：EP04740985.9

申请日：2004-07-14

申请人： Sanofi-Aventis Deutschland GmbH

发明人： WAGNER, Holger ,  SCHOENAFINGER, Karl ,  JAEHNE, Gerhard ,  GAUL, Holger ,  BUNING, Christian ,  TSCHANK, Georg ,  WERNER, Ulrich

IPC分类号： C07D513/04 ,  A61K31/415

CPC分类号： C07D487/04

摘要： The invention relates to compounds of formula (I), wherein the radicals have the meanings indicated in the text, the stereoisomeric forms thereof, the physiologically acceptable salts thereof, and methods for the production thereof. The inventive compounds are suitable for the treatment of metabolic diseases such as type 2 diabetes.

公开(公告)号：EP3126336A1

公开(公告)日：2017-02-08

申请号：EP15713528.6

申请日：2015-04-02

申请人： Sanofi

发明人： SCHWINK, Lothar ,  BUNING, Christian ,  GLOMBIK, Heiner ,  GOSSEL, Matthias ,  KADEREIT, Dieter ,  HALLAND, Nis ,  LOHMANN, Matthias ,  PÖVERLEIN, Christoph ,  RITTER, Kurt

IPC分类号： C07D231/56 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/4745 ,  C07D249/18 ,  C07D471/04 ,  A61P3/00

CPC分类号： C07D471/04 ,  A61K31/155 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/702 ,  A61K45/06 ,  C07D231/56 ,  C07D249/18 ,  C07D401/14 ,  A61K2300/00

摘要： The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

摘要翻译： 所述substituiertem稠合杂环化合物是GPR119调节剂和用于治疗糖尿病，肥胖，血脂异常和相关疾病的预防和/或治疗是有用的。 本发明进一步更涉及使用的substituiertem稠合杂环化合物作为医药品的活性成分，以及包含它们的药物组合物。